209 related articles for article (PubMed ID: 31479568)
1. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Gervaso L; Montero AJ; Jia X; Khorana AA
J Thromb Haemost; 2020 Jan; 18(1):162-168. PubMed ID: 31479568
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
3. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
5. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
6. Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data.
Yan MM; Wu SS; Qi YP; Li ZR; Zhang Q; Zhao H; Zhong MK; Qiu XY
Expert Opin Drug Saf; 2022 Feb; 21(2):277-283. PubMed ID: 34581647
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Prowell TM; Bloomquist E; Tang S; Wedam SB; Royce M; Krol D; Osgood C; Ison G; Sridhara R; Pazdur R; Beaver JA; Amiri-Kordestani L
Lancet Oncol; 2021 Nov; 22(11):1573-1581. PubMed ID: 34656225
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
[TBL] [Abstract][Full Text] [Related]
10. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Watson NW; Wander SA; Shatzel JJ; Al-Samkari H
Cancer; 2022 Sep; 128(17):3224-3232. PubMed ID: 35767226
[TBL] [Abstract][Full Text] [Related]
11. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
13. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study.
Groot OQ; Ogink PT; Paulino Pereira NR; Ferrone ML; Harris MB; Lozano-Calderon SA; Schoenfeld AJ; Schwab JH
Clin Orthop Relat Res; 2019 Jul; 477(7):1674-1686. PubMed ID: 31135550
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and impact of screening for venous thromboembolism in treatment-naive lung cancer patients-Results of a prospective cohort study.
Muthu V; Narasimhan RL; Prasad KT; Ahluwalia J; Garg M; Behera D; Singh N
Indian J Cancer; 2022; 59(2):203-211. PubMed ID: 33753627
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
[TBL] [Abstract][Full Text] [Related]
16. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Clinical Characteristic of Venous Thromboembolism in Gynecologic Oncology Patients attending King Chulalongkorn Memorial Hospital over a 10 Year Period.
Oranratanaphan S; Termrungruanglert W; Khemapech N
Asian Pac J Cancer Prev; 2015; 16(15):6705-9. PubMed ID: 26434898
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.
Watson NW; Shatzel JJ; Al-Samkari H
J Thromb Haemost; 2023 Apr; 21(4):758-770. PubMed ID: 36696184
[TBL] [Abstract][Full Text] [Related]
20. High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients.
Groot OQ; Ogink PT; Janssen SJ; Paulino Pereira NR; Lozano-Calderon S; Raskin K; Hornicek F; Schwab JH
Clin Orthop Relat Res; 2018 Oct; 476(10):2052-2061. PubMed ID: 30179923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
